34
Participants
Start Date
April 3, 2017
Primary Completion Date
March 8, 2019
Study Completion Date
March 8, 2019
25mcg rhPTH(1-84)
Participants will receive rhPTH(1-84) as twice-daily regimen (12 hours apart) of two 25mcg doses without calcium in cohort 1 and with calcium in cohort 3.
50mcg rhPTH(1-84)
Participants will receive rhPTH(1-84) as twice daily regimen (12 hours apart) of two 50mcg doses without calcium in cohort 2 and with calcium in cohort 4
100mcg rhPTH(1-84)
Participants will receive rhPTH(1-84) as once-daily regimen of one 100 mcg dose without calcium in cohort 1 and 2 and with calcium in cohort 3 and 4 in the morning.
Semmelweis Egyetem, Budapest
Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont, Szeged
Pécsi Tudományegyetem, Pécs
Aarhus Universitetshospital, Aarhus N
Columbia University Medical Center, New York
Thomas Jefferson University, Philadelphia
New Orleans Center for Clinical Research (NOCCR) - Knoxville, Knoxville
Ohio State University Wexner Medical Center, Columbus
Indiana University, Indianapolis
Mayo Clinic - PPDS, Rochester
Crescent City Clinical Research Center, LLC, Metairie
Providence Clinical Research, North Hollywood
University Of Kentucky School of Medicine, Lexington
Massachusetts General Hospital, Boston
CHU de Quebec-Universite Laval, Québec
Lead Sponsor
Shire
INDUSTRY